Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
Abrao MS, Surrey E, Gordon K, Snabes MC, Wang H, Ijacu H, Taylor HS. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients. BMC Women's Health 2021, 21: 246. PMID: 34134684, PMCID: PMC8210385, DOI: 10.1186/s12905-021-01385-3.Peer-Reviewed Original ResearchConceptsNon-menstrual pelvic painEndometriosis-associated painBaseline characteristicsSubgroup interactionsEndometriosis Health Profile-30Severe endometriosis-associated painGonadotropin-releasing hormone receptor antagonistEfficacy of elagolixPatient-reported reductionsPhase 3 studyHealth-related qualityReal-world patientsHormone receptor antagonistSubgroup of womenSignificant treatmentPercentage of womenAnalgesic usePelvic painMonth 3Receptor antagonistPrevious historyMost subgroupsPainPatient typesEndometriosis disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply